Martín, J.A.L.
SEOM guidelines for the management of Malignant Melanoma 2015. [guía clínica] - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 - 17(12):1030-5.
Formato Vancouver:
Berrocal A, Arance A, Espinosa E, Castaño AG, Cao MG, Larriba J et al. SEOM guidelines for the management of Malignant Melanoma 2015. Clin Transl Oncol. 2015 Dec;17(12):1030-5.
PMID: 26669314
PMC4689745
Contiene 25 referencias
All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.
SEOM guidelines for the management of Malignant Melanoma 2015. [guía clínica] - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015 - 17(12):1030-5.
Formato Vancouver:
Berrocal A, Arance A, Espinosa E, Castaño AG, Cao MG, Larriba J et al. SEOM guidelines for the management of Malignant Melanoma 2015. Clin Transl Oncol. 2015 Dec;17(12):1030-5.
PMID: 26669314
PMC4689745
Contiene 25 referencias
All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.
